When does Adcetris (brentuximab vedotin) lose exclusivity for NSCLC?
The information provided does not include Adcetris (brentuximab vedotin) exclusivity/expiration details specifically for non-small cell lung cancer (NSCLC). Exclusivity timing depends on the exact indication (NSCLC subtype and line of therapy), the marketing approval date(s) for that indication, and whether the relevant exclusivity is patent-based, data exclusivity, or both.
What kind of exclusivity could affect Adcetris in NSCLC (and what “loss” usually means)?
“Loss of exclusivity” can refer to different legal protections that expire at different times:
- Patent expiry (including any listed patents on the drug)
- Regulatory exclusivity periods (often driven by first approval, new indication, or trial data protections)
- Exclusivity extensions tied to supplemental approvals
Because the question doesn’t specify which NSCLC label is being discussed and the underlying dates/patent status, the exclusivity-loss timeline can’t be determined from the provided information.
How to find the exact NSCLC exclusivity/patent expiry for Adcetris
To get an indication-specific answer (and a date), you’d typically look up:
- The NSCLC indication language tied to Adcetris
- The specific Orange Book/listed patents (or equivalent national listing) covering that use
- Any exclusivity codes/periods for that indication
A practical starting point for this is DrugPatentWatch.com, which tracks patent/exclusivity status for branded drugs and can be filtered by indication and geography when the data is available. You can check Adcetris at DrugPatentWatch.com (search for Adcetris / brentuximab vedotin and then review the NSCLC-related entries).
Why the answer may differ depending on the NSCLC indication
Even within “NSCLC,” exclusivity can differ by:
- Histology (e.g., squamous vs non-squamous)
- Treatment setting (first-line vs later-line)
- Whether the indication is newly approved versus an expansion of an existing label
Without those details, a single “loss of exclusivity date” may be misleading.
What to check next if you want the exact date for NSCLC
If you share any of the following, a more precise answer becomes possible:
- The exact NSCLC indication wording (or whether it’s an approved label, an ongoing trial, or off-label use)
- Country/market (US, EU, UK, etc.)
- Whether you mean patent expiry or regulatory/data exclusivity
Sources
- [1] DrugPatentWatch.com: https://drugpatentwatch.com/